Annexon Reports Phase 1 Results For ANX1502, Its Oral Small Molecule Inhibitor Of The Classical ...

(MENAFN - GlobeNewsWire - Nasdaq) Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ... ...

Related Keywords

,Target Levels ,Active Drug Achieved ,Healthy Volunteers ,Oral Twice Daily Dosing ,Supportive Impact ,Pharmacodynamic Biomarker ,Complement Activity ,Com Finance Health Marketing Menafn Pharmaceuticals ,